What Is NAD+? Where It Came From, and When

What is NAD+? It is a coenzyme, nicotinamide adenine dinucleotide, that every cell you have already makes, spends and rebuilds continuously. It is not a peptide, and it is not new. What is new is the vial, and the distance between the age of the biochemistry and the age of the product is most of the story.

Sorted by when things actually happened, the account splits cleanly in two. There is a long stretch of settled biology, then a short recent stretch of commerce. Almost everything a buyer is shown belongs to the second stretch, while the credibility being borrowed belongs to the first.

What is NAD+, and why it sits apart from everything else sold this way

Most compounds discussed on pages like this one are synthetic peptides: chains assembled in a laboratory, with a sequence and an origin in somebody's research programme. This one is not. It is endogenous, present in every cell in your body at a concentration your own metabolism regulates, and it was doing its work long before anyone had a name for it.

That work is electron transport. In the reactions that release energy from food, NAD+ accepts electrons and becomes NADH. Further along a pathway, NADH hands them over and reverts. The pool is not filled once and then drained. It turns over constantly, and keeping that in view changes how much a single scheduled appointment could plausibly mean.

A second role was recognised much later, and it is the one that built the market. Certain enzymes do not borrow the coenzyme, they consume it, cleaving the molecule and leaving nicotinamide behind. Sirtuins, PARP enzymes and CD38 all work this way. Because those enzymes sit inside DNA repair, metabolic signalling and immune activity, a piece of textbook metabolism was reframed as a candidate lever on ageing. That reframing was a change in interpretation. It was not the arrival of a clinical result, and the two get quoted as though they were the same event.

The order it was found in, from fermentation to a deficiency disease

The first appearance was indirect. Early biochemists studying fermentation in yeast extracts found that the process required a small, heat stable factor alongside the enzymes, and they gave it a placeholder name before anyone knew its structure. Identifying that factor as the dinucleotide came later, out of work on the chemistry of yeast preparations rather than out of any interest in human health.

The human connection arrived through nutrition. Nicotinamide, the vitamin B3 form, was identified as the dietary factor whose absence produces pellagra, a deficiency disease with skin, gut and neurological features. This is the point in the sequence where the molecule became medically important in people, and it is worth being precise about what it established: severe dietary deficiency causes a specific illness, and correcting the deficiency corrects the illness. It says nothing about giving extra to someone who is not deficient. Almost every misuse of this compound's history skips from the pellagra work straight to a wellness claim, and the step between them was never taken.

Then the sequence went quiet for a long time. The coenzyme was in the textbooks, its role in metabolism was uncontroversial, and nobody was selling it.

The second discovery, which turned a coenzyme into a product

Interest returned when the consuming enzymes were characterised. Once it was clear that a set of regulatory enzymes destroy NAD+ as part of their normal function, the size of the cellular pool stopped looking like a fixed background quantity and started looking like something that could be depleted.

Alongside that came reports of declining tissue concentrations with age, described in rodent tissues and in some human tissue analyses. Those measurements are real, and they are measurements of concentration in tissue. They are not measurements of how anyone feels, how long anyone lives, or what happens if the concentration is pushed back up.

The commercial argument assembled itself from those two pieces: levels fall with age, enzymes that matter depend on the levels, therefore raising the levels should help. Each link in that chain is a hypothesis. Chained together they read as a conclusion, which is how a mechanism becomes a marketing claim without any intervening trial.

Where the precursors arrived, and what they actually are

The next stage is the one most often collapsed into the previous one. Rather than give the coenzyme itself, researchers gave the smaller molecules cells use to build it: nicotinamide riboside and nicotinamide mononucleotide, taken by mouth. These are precursors. They are absorbed, and the cell assembles the coenzyme from them using pathways it already runs.

This is where the human trial literature sits. When you read that this molecule has been studied extensively in people, the studies being counted are overwhelmingly precursor studies, taken orally. The most consistent human finding from that work is that oral nicotinamide riboside raises NAD+ measured in blood. That is a real result in humans, and it is a result about a blood concentration.

The literature overall is enormous, more than seventy six thousand records in PubMed mentioning this coenzyme, and the vast majority of it is basic cell biology rather than clinical work in people. Volume of publication is not evidence of benefit, and it is certainly not evidence about a different route of administration.

The step from a capsule to a drip, which the evidence did not take

Injecting or infusing the intact coenzyme is a separate intervention from swallowing a precursor. It is not a stronger version of the same thing.

Anyone claiming otherwise has to explain what happens between the vein and the inside of a cell. The intact molecule is large and charged, and cells are much better equipped to import the small precursors than the assembled coenzyme. Extracellular enzymes break it down, and what actually reaches the inside of a cell is a question about metabolism rather than a matter of arithmetic on the label. Tracing work in mice has reported that the coenzyme given by mouth is broken apart into smaller pieces before it is absorbed, which is a rodent finding about the oral route and not a settled account of the intravenous one.

None of this proves an infusion does nothing. It establishes something narrower and more useful: the precursor trials are not evidence for the drip, and the two must be kept apart in any honest summary.

The names on the label, and which stage each one belongs to

Six words circulate as though they were interchangeable, and each one entered the story at a different point.

Niacin, or nicotinic acid, is the form associated with flushing, and it is the one the pellagra work made famous. Nicotinamide is the other vitamin B3 form, and it does not produce the flush. NAD+ and NADH are the two states of the same coenzyme, oxidised and reduced, and a product labelled with either is claiming to supply the assembled molecule. Nicotinamide riboside and nicotinamide mononucleotide are the two precursors that carry the modern supplement literature, and they are what almost every recent human trial actually administered.

A label that says NAD and a label that says NMN describe different purchases, and a summary that treats them as one blurs the only distinction that matters here. When a page cites a trial in support of a drip, the first question is which of these six words appears in the trial, and the answer is usually one of the last two.

There is one more term worth separating out, because it belongs to the biology rather than to a shelf. The salvage pathway is the route cells use to rebuild the coenzyme from nicotinamide after a consuming enzyme has broken it apart. It runs continuously in every cell, it is the reason the pool exists at a steady concentration at all, and it means a person is never simply out of the molecule in the way a fuel tank is empty. Any product claiming to top it up is competing with a pathway that has been running all day.

The questions this ordering raises